After a tumultuous year, a popular virtual care platform is trying its hand in a competitive blood testing market.
Hims & Hers—the virtual care platform with about 2.5 million subscribers—will now offer laboratory testing through Quest Diagnostics. Customers will have access to more than 120 biomarker tests across 10 markets of health and longevity: heart health, liver health, metabolic health, immune defense, hormone health, thyroid health, inflammation and stress, nutrients, kidney health and blood.
Hims & Hers believes that this offering will align with consumer preferences, according to Dr. Pat Carroll, the company’s chief medical officer. Patients want more data to help inform their health decisions—but with a national shortage of primary care physicians, many find it challenging to access providers who can order preventative screenings. They’re now looking to bypass the complicated traditional medical system, seeking answers and interpreting results on their own terms. “People are now much more aware of their own health, and they want to be more proactive about it and move away from this paternalistic system that I practiced in for years, the doctor says something and follows the doctor’s instructions,” Carroll, a primary care doctor by training, told Newsweek in an exclusive interview. “People are reading a lot more online about their own health care.” Carroll hopes that by making it easier for patients to access laboratory testing and results, Hims & Hers will “empower them” to “make informed medical decisions” and “advance their own health care.” Hims & Hers customers can choose from two blood testing plans, paying $199 to test 50 blood biomarkers or $499 to test more than 120. Demand for laboratory services is on the rise, according to the Centers for Disease Control and Prevention . Approximately 14 billion lab tests are conducted in the United States each year, and 70 percent of medical decisions depend on them, per the agency. But doctors aren’t the only ones who making decisions based off bloodwork. Patients also want faster access to their lab results, with nearly 96 percent indicating that they would prefer to receive non-normal results in their online patient portal as soon as possible—even if they arrive before a doctor can analyze them, according to a recent survey published in JAMA Network Open. Plus, patients are increasingly demanding to initiate tests on their own. National laboratory networks, including Quest Diagnostics and Labcorp, have added “on-demand” options that allow patients to pay for certain workups out of pocket, without physician oversight. In 2022, Quest reported more than 900,000 consumer-initiated test requisitions, leading them to expand their menu for these services throughout 2023 and 2024. Through Hims & Hers’ model, patients will be able to choose from two blood testing plans. The base offering includes one yearly blood draw that assesses 50 biomarkers for a $199 fee. If patients opt for the advanced offering, they’ll pay $499 for two yearly blood draws that capture more than 120 biomarkers. Under both plans, patients’ results will be reviewed by Hims & Hers medical providers. They might recommend treatment on the platform, if it’s available, or refer them elsewhere to address immediate concerns. “Our providers review the results, and then on our app, we actually give clear direction of what’s normal, what’s not normal, what needs to be addressed soon, versus what can wait,” Carroll said, “and then we provide education, both on our app, but also from our providers outreach with the results to guide them to where they need to be.” Laboratory tests will be conducted at Quest Diagnostics, which has more than 6,000 locations across all 50 states. Results can typically be expected within two weeks of the test, according to Hims & Hers. Close-up of a sign for Quest Diagnostics’ laboratory in Lafayette, California, on April 9, 2022. Hims & Hers is entering an increasingly competitive laboratory services environment. The direct-to-consumer lab testing market was valued at $3.62 billion in 2025 and is expected to grow to nearly $6 billion by 2030. Earlier this month, the wearable technology company Oura announced on-demand health panels, offering personalized results and AI-powered analysis through its app. Other direct-to-consumer testing companies are showing promise, too. The virtual platform Superpower raised $30 million in its Series A funding round this spring, and recently launched a $199 annual membership with access to more than 100 biomarker tests each year . And Forum Health, which launched a “Labs Direct” offering in 2023, claimed a spot o...
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Venezuela mobilizes forces as largest US warship enters regionVenezuela says it is launching a “massive mobilization” of military personnel, weapons and equipment in response to the build-up of US warships and troops in the Caribbean Sea. CNN’s Stefano Pozzebon reports from Caracas.
Read more »
CNCF Technology Radar: Cloud Native AI Enters Its Production EraThe CNCF Tech Radar report concludes that cloud native infrastructure is no longer optional for AI and ML practitioners.
Read more »
CNCF Technology Radar: Cloud Native AI Enters Its Production EraThe CNCF Tech Radar report concludes that cloud native infrastructure is no longer optional for AI and ML practitioners.
Read more »
Jack Schlossberg, JFK’s Grandson, Enters Race for Nadler’s NYC House SeatSchlossberg, the only son of Caroline Kennedy, would represent parts of New York City if elected to succeed Nadler.
Read more »
As One Pelosi Exits, Another Enters: Christine Launches State Senate BidSource of breaking news and analysis, insightful commentary and original reporting, curated and written specifically for the new generation of independent and conservative thinkers.
Read more »
Seed Library NYC, the hottest bar underneath NoMadSeedless Library NYC enters Manhattan's mixology world as its latest—and possibly best—addition.
Read more »